KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $100.0 million.

  • Sarepta Therapeutics' Net Cash Flow rose 15384.43% to $100.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $412.8 million, marking a year-over-year increase of 21873.19%. This contributed to the annual value of $674.6 million for FY2024, which is 22450.9% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Net Cash Flow stood at $100.0 million for Q3 2025, which was up 15384.43% from $269.7 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Net Cash Flow high stood at $905.2 million for Q4 2024, and its period low was -$882.0 million during Q1 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$43.7 million (2024), whereas its average is -$46.6 million.
  • In the last 5 years, Sarepta Therapeutics' Net Cash Flow surged by 171454.53% in 2021 and then crashed by 7552657.89% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Net Cash Flow (Quarter) stood at $517.3 million in 2021, then tumbled by 113.89% to -$71.8 million in 2022, then tumbled by 62.95% to -$117.1 million in 2023, then soared by 873.16% to $905.2 million in 2024, then plummeted by 88.95% to $100.0 million in 2025.
  • Its last three reported values are $100.0 million in Q3 2025, $269.7 million for Q2 2025, and -$862.1 million during Q1 2025.